Approach to treatment of children with pulmonary tuberculosis (known or presumed drug susceptible)

TB: tuberculosis; WHO: World Health Organization; CDC: United States Centers for Disease Control and Prevention.

* The shortened (4-month regimen) may be used for treatment for nonsevere, smear-negative, presumed drug-susceptible disease (defined as pulmonary TB confined to one lobe). Exclusions include cavitary disease, miliary TB, complex pleural effusion, clinically significant airway obstruction, and peripheral lymph node involvement.

¶ While some favor rifapentine-moxifloxacin-based 4-month regimen over the traditional regimen given the shorter duration, others favor the traditional regimen pending further outcome data with the rifapentine-moxifloxacin-based 4-month regimen.